




Instance: composition-en-2a9a5e18ea12db555fa903817024b9fe
InstanceOf: CompositionUvEpi
Title: "Composition for mirapexin Package Leaflet"
Description:  "Composition for mirapexin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpab95c79ec7ceeaa38bc48db0210fa26a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - mirapexin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What MIRAPEXIN is and what it is used for</li>
<li>What you need to know before you take MIRAPEXIN</li>
<li>How to take MIRAPEXIN</li>
<li>Possible side effects</li>
<li>How to store MIRAPEXIN</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What mirapexin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What mirapexin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>MIRAPEXIN contains the active substance pramipexole and belongs to a group of medicines known 
as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine 
receptors triggers nerve impulses in the brain that help to control body movements.
MIRAPEXIN is used to:
-
treat the symptoms of primary Parkinson s disease in adults. It can be used alone or in 
combination with levodopa (another medicine for Parkinson s disease).
-
treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take mirapexin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take mirapexin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take MIRAPEXIN</h2>
<p>if you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in
section 6).
Warnings and precautions
Talk to your doctor before taking MIRAPEXIN. Tell your doctor if you have (had) or develop any 
medical conditions or symptoms, especially any of the following:
-
Kidney disease
-
Hallucinations (seeing, hearing or feeling things that are not there). Most hallucinations are visual.
-
Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). If you have advanced 
Parkinson s disease and are also taking levodopa, you might develop dyskinesia during the up-
titration of MIRAPEXIN.
-
Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)). In 
particular, you may experience forward flexion of the head and neck (also called antecollis), 
forward bending of the lower back (also called camptocormia) or sidewards bending of the back 
(also called pleurothotonus or Pisa Syndrome).
-
Sleepiness and episodes of suddenly falling asleep
-
Psychosis (e.g. comparable with symptoms of schizophrenia)
-
Vision impairment. You should have regular eye examinations during treatment with 
MIRAPEXIN.
-
Severe heart or blood vessels disease. You will need to have your blood pressure checked 
regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in 
blood pressure on standing up).
-
Restless legs augmentation syndrome. If you experience that symptoms start earlier than usual in 
the evening (or even the afternoon), are more intense or involve larger parts of the affected limbs 
or involve other limbs. Your doctor may lower your dose or stop the treatment.
Tell your doctor if you or your family/carer notices that you are developing urges or cravings to 
behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry 
out certain activities that could harm yourself or others. These are called impulse control disorders and 
can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high 
sex drive or preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to 
adjust or stop your dose.
Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling 
elated or over-excited) or delirium (decreased awareness, confusion or loss of reality). Your doctor 
may need to adjust or stop your dose.
Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or 
pain after stopping or reducing your MIRAPEXIN treatment. If the problems persist more than a few 
weeks, your doctor may need to adjust your treatment.
Tell your doctor if you are developing an inability of keeping your body and neck straight and upright 
(axial dystonia). If this happens, your doctor may want to adjust or change your medication.
Children and adolescents
MIRAPEXIN is not recommended for use in children or adolescents under 18 years.
Other medicines and MIRAPEXIN
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This includes medicines, herbal remedies, health foods or supplements that you have 
obtained without a prescription.
You should avoid taking MIRAPEXIN together with antipsychotic medicines.
Take care if you are taking the following medicines:
-
cimetidine (to treat excess stomach acid and stomach ulcers)
-
amantadine (which can be used to treat Parkinson s disease)
-
mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia)
-
zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a 
disease of the human immune system)
-
cisplatin (to treat various types of cancers)
-
quinine (which can be used for the prevention of painful night-time leg cramps and for the 
treatment of a type of malaria known as falciparum malaria (malignant malaria))
-
procainamide (to treat irregular heart beat)
If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start 
treatment with MIRAPEXIN.
Take care if you are using any medicines that calm you down (have a sedative effect) or if you are 
drinking alcohol. In these cases MIRAPEXIN may affect your ability to drive and operate machinery.
MIRAPEXIN with food, drink and alcohol
You should be cautious while drinking alcohol during treatment with MIRAPEXIN.
MIRAPEXIN can be taken with or without food.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before taking this medicine. Your doctor will then discuss with you if you 
should continue to take MIRAPEXIN.
The effect of MIRAPEXIN on the unborn child is not known. Therefore, do not take MIRAPEXIN if 
you are pregnant unless your doctor tells you to do so.
MIRAPEXIN should not be used during breast-feeding. MIRAPEXIN can reduce the production of 
breast milk. Also, it can pass into the breast milk and can reach your baby. If use of MIRAPEXIN is 
unavoidable, breast-feeding should be stopped.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
MIRAPEXIN can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, 
do not drive or use machines.
MIRAPEXIN has been associated with sleepiness and episodes of suddenly falling asleep, particularly 
in patients with Parkinson s disease. If you experience these side effects, you must not drive or operate 
machinery. You should tell your doctor if this occurs.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take mirapexin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take mirapexin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure. The doctor will advise you on the right dosing.
You can take MIRAPEXIN with or without food. Swallow the tablets with water.
Parkinson s disease
The daily dose is to be taken divided into 3 equal doses.
During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg three times a day (equivalent 
to 0.264 mg daily):
1st week
Number of tablets
1 tablet MIRAPEXIN 0.088 mg three times a day
Total daily dose (mg)
0.This will be increased every 5-7 days as directed by your doctor until your symptoms are controlled 
(maintenance dose).
2nd week
3rd week
Number of tablets
1 tablet MIRAPEXIN
0.18 mg three times a day
OR
2 tablets MIRAPEXIN
0.088 mg three times a day
1 tablet MIRAPEXIN
0.35 mg three times a day
OR
2 tablets MIRAPEXIN
0.18 mg three times a day
Total daily dose (mg)
0.1.1
The usual maintenance dose is 1.1 mg per day. However, your dose may have to be increased even 
further. If necessary, your doctor may increase your tablet dose up to a maximum of 3.3 mg of 
pramipexole a day. A lower maintenance dose of three MIRAPEXIN 0.088 mg tablets a day is also 
possible.
Lowest maintenance dose
Highest maintenance dose
Number of tablets
1 tablet MIRAPEXIN
0.088 mg three times a day
1 tablet MIRAPEXIN
0.7 mg and 1 tablet 
MIRAPEXIN 0.35 mg
three times a day
Total daily dose (mg)
0.3.Patients with kidney disease
If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. In this case, 
you will have to take the tablets only once or twice a day. If you have moderate kidney disease, the 
usual starting dose is 1 tablet MIRAPEXIN 0.088 mg twice a day. In severe kidney disease, the usual 
starting dose is just 1 tablet MIRAPEXIN 0.088 mg a day.
Restless Legs Syndrome
The dose is usually taken once a day, in the evening, 2-3 hours before bedtime.
During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg once a day (equivalent to 
0.088 mg daily):
1st week
Number of tablets
1 tablet MIRAPEXIN 0.088 mg
Total daily dose (mg)
0.This will be increased every 4-7 days as directed by your doctor until your symptoms are controlled 
(maintenance dose).
2nd week
3rd week
4th week
Number of 
tablets
1 tablet MIRAPEXIN
0.18 mg
OR
2 tablets MIRAPEXIN
0.088 mg
1 tablet MIRAPEXIN
0.35 mg
OR
2 tablets MIRAPEXIN
0.18 mg 
OR
4 tablets MIRAPEXIN
0.088 mg
1 tablet MIRAPEXIN
0.35 mg and 1 tablet 
MIRAPEXIN 0.18 mg
OR
3 tablets MIRAPEXIN
0.18 mg
OR
6 tablets MIRAPEXIN
0.088 mg
Total daily 
dose (mg)
0.0.0.The daily dose should not exceed 6 tablets MIRAPEXIN 0.088 mg or a dose of 0.54 mg (0.75 mg 
pramipexole salt).
If you stop taking your tablets for more than a few days and want to restart the treatment, you must 
start again at the lowest dose. You can then build up the dose again, as you did the first time. Ask your 
doctor for advice.
Your doctor will review your treatment after 3 months to decide whether or not to continue the 
treatment.
Patients with kidney disease
If you have severe kidney disease, MIRAPEXIN may not be a suitable treatment for you.
If you take more MIRAPEXIN than you should
If you accidentally take too many tablets,
-
Contact your doctor or nearest hospital casualty department immediately for advice.
-
You may experience vomiting, restlessness, or any of the side effects as described in section 4. Possible side effects .
If you forget to take MIRAPEXIN
Do not worry. Simply leave out that dose completely and then take your next dose at the right time. 
Do not try to make up for the missed dose.
If you stop taking MIRAPEXIN
Do not stop taking MIRAPEXIN without first talking to your doctor. If you have to stop taking this 
medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.
If you suffer from Parkinson s disease you should not stop treatment with MIRAPEXIN abruptly. A 
sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome 
which may represent a major health risk. The symptoms include:
-
akinesia (loss of muscle movement)
-
rigid muscles
-
fever
-
unstable blood pressure
-
tachycardia (increased heart rate)
-
confusion
-
depressed level of consciousness (e.g. coma)
If you stop or reduce MIRAPEXIN you may also develop a medical condition called dopamine 
agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating or 
pain. If you experience these symptoms you should contact your physician.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Evaluation 
of these side effects is based on the following frequencies:
Very common
may affect more than 1 in 10 people
Common
may affect up to 1 in 10 people
Uncommon
may affect up to 1 in 100 people
Rare
may affect up to 1 in 1,000 people
Very rare
may affect up to 1 in 10,000 people
Not known
Frequency cannot be estimated from the available data
If you suffer from Parkinson s disease, you may experience the following side effects:
Very common:
-
Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)
-
Sleepiness 
-
Dizziness
-
Nausea (sickness)
Common:
-
Urge to behave in an unusual way
-
Hallucinations (seeing, hearing or feeling things that are not there)
-
Confusion
-
Tiredness (fatigue)
-
Sleeplessness (insomnia)
-
Excess of fluid, usually in the legs (peripheral oedema)
-
Headache
-
Hypotension (low blood pressure)
-
Abnormal dreams
-
Constipation
-
Visual impairment
-
Vomiting (being sick)
-
Weight loss including decreased appetite
Uncommon:
-
Paranoia (e.g. excessive fear for one s own well-being)
-
Delusion
-
Excessive daytime sleepiness and suddenly falling asleep
-
Amnesia (memory disturbance)
-
Hyperkinesia (increased movements and inability to keep still)
-
Weight increase
-
Allergic reactions (e.g. rash, itching, hypersensitivity)
-
Fainting
-
Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)<em> -
Inappropriate antidiuretic hormone secretion</em> -
Restlessness
-
Dyspnoea (difficulties to breathe)
-
Hiccups
-
Pneumonia (infection of the lungs)
-
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to 
you or others, which may include:
-
Strong impulse to gamble excessively despite serious personal or family consequences.
-
Altered or increased sexual interest and behaviour of significant concern to you or to others, 
for example, an increased sexual drive.
-
Uncontrollable excessive shopping or spending
-
Binge eating (eating large amounts of food in a short time period) or compulsive eating 
(eating more food than normal and more than is needed to satisfy your hunger)<em> -
Delirium (decreased awareness, confusion, loss of reality)
Rare:
-
Mania (agitation, feeling elated or over-excited)
Not known:
-
After stopping or reducing your MIRAPEXIN treatment: Depression, apathy, anxiety, fatigue, 
sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).
Tell your doctor if you experience any of these behaviours; he will discuss ways of managing or 
reducing the symptoms.
For the side effects marked with * a precise frequency estimation is not possible, since these side 
effects were not observed in clinical studies among 2,762 patients treated with pramipexole. The 
frequency category is probably not greater than  uncommon .
If you suffer from Restless Legs Syndrome, you may experience the following side effects:
Very common:
-
Nausea (sickness)
-
Symptoms that start earlier than usual, are more intense or involve other limbs (Restless legs
augmentation syndrome).
Common:
-
Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness
-
Tiredness (fatigue)
-
Headache
-
Abnormal dreams
-
Constipation
-
Dizziness
-
Vomiting (being sick)
Uncommon:
-
Urge to behave in an unusual way</em> -
Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)<em> -
Inappropriate antidiuretic hormone secretion</em> -
Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)
-
Hyperkinesia (increased movements and inability to keep still)<em> -
Paranoia (e.g. excessive fear for one s own well-being)</em> -
Delusion<em> -
Amnesia (memory disturbance)</em> -
Hallucinations (seeing, hearing or feeling things that are not there)
-
Confusion
-
Excessive daytime sleepiness and suddenly falling asleep 
-
Weight increase
-
Hypotension (low blood pressure)
-
Excess of fluid, usually in the legs (peripheral oedema)
-
Allergic reactions (e.g. rash, itching, hypersensitivity)
-
Fainting
-
Restlessness
-
Visual impairment
-
Weight loss including decreased appetite
-
Dyspnoea (difficulties to breathe)
-
Hiccups
-
Pneumonia (infection of the lungs)<em> -
Inability to resist the impulse, drive or temptation to perform an action that could be harmful to 
you or others, which may include:
-
Strong impulse to gamble excessively despite serious personal or family consequences.</em> -
Altered or increased sexual interest and behaviour of significant concern to you or to others, 
for example, an increased sexual drive.<em> -
Uncontrollable excessive shopping or spending</em> -
Binge eating (eating large amounts of food in a short time period) or compulsive eating 
(eating more food than normal and more than is needed to satisfy your hunger)<em> -
Mania (agitation, feeling elated or over-excited)</em> -
Delirium (decreased awareness, confusion, loss of reality)* Not known:
-
After stopping or reducing your MIRAPEXIN treatment: Depression, apathy, anxiety, fatigue, 
sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).
Tell your doctor if you experience any of these behaviors; he will discuss ways of managing or 
reducing the symptoms.
For the side effects marked with * a precise frequency estimation is not possible, since these side 
effects were not observed in clinical studies among 1,395 patients treated with pramipexole. The 
frequency category is probably not greater than  uncommon .
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store mirapexin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store mirapexin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date 
refers to the last day of that month.
Do not store above 30 C.
Store in the original package to protect the tablets from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What MIRAPEXIN contains
The active substance is pramipexole.
Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg, 
0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively.
The other ingredients are mannitol, maize starch, anhydrous colloidal silica, povidone K 25 and
magnesium stearate.
What MIRAPEXIN looks like and contents of the pack
MIRAPEXIN 0.088 mg tablets are white, of round shape, flat, and without scoring.
MIRAPEXIN 0.18 mg tablets and MIRAPEXIN 0.35 mg tablets are white, of oval shape, and flat. 
Tablets are scored on both sides and breakable in halves.
MIRAPEXIN 0.7 mg tablets are white, of round shape, and flat. Tablets are scored on both sides and 
breakable in halves.
All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P6, 
P7, P8, or P9 on the other side, representing the tablet strengths 0.088 mg, 0.18 mg, 0.35 mg, and
0.7 mg, respectively.
All strengths of MIRAPEXIN are available in aluminium blister strips of 10 tablets per strip, in 
cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes may be marketed.
Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH &amp; Co. KG
Binger Strasse 55216 Ingelheim am Rhein
Germany
Rottendorf Pharma GmbH
Ostenfelder Strasse 51   59320 Ennigerloh
Germany
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
France
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
SCS Boehringer Ingelheim Comm.V
T l/Tel: +32 2 773 33 Lietuva
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Lietuvos filialas
Tel: +370 5 2595 
           .   -</p>
<p>: +359 2 958 79 Luxembourg/Luxemburg
SCS Boehringer Ingelheim Comm.V
T l/Tel: +32 2 773 33  esk  republika
Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 Magyarorsz g
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Magyarorsz gi Fi ktelepe
Tel: +36 1 299 89 Danmark
Boehringer Ingelheim Danmark A/S
Tlf: +45 39 15 88 Malta
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9Deutschland
BIOTHERAX biochemisch-pharmazeutische
Gesellschaft mbH
Tel: +49 (0) 800 77 90 Nederland
Boehringer Ingelheim b.v.
Tel: +31 (0) 800 22 55 Eesti
Boehringer Ingelheim RCV GmbH &amp; Co KG
Eesti filiaal
Tel: +372 612 8Norge
Boehringer Ingelheim Norway KS
Tlf: +47 66 76 13<br />
Boehringer Ingelheim Ellas A.E.
T : +30 2 10 89 06  sterreich
Boehringer Ingelheim RCV GmbH &amp; Co KG
Tel: +43 1 80 105-7Espa a
Boehringer Ingelheim Espa a, S.A.
Tel: +34 93 404 51 Polska
Boehringer Ingelheim Sp.zo.o.
Tel: +48 22 699 0 France
Boehringer Ingelheim France S.A.S.
T l: +33 3 26 50 45 Portugal
Boehringer Ingelheim Portugal, Lda.
Tel: +351 21 313 53 Hrvatska
Boehringer Ingelheim Zagreb d.o.o.
Tel: +385 1 2444 Rom nia
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Viena - Sucursala Bucure ti
Tel: +40 21 302 28 Ireland
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9Slovenija
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Podru nica Ljubljana
Tel: +386 1 586 40  sland
Vistor hf.
S mi: +354 535 7Slovensk  republika
Boehringer Ingelheim RCV GmbH &amp; Co KG
organiza n  zlo ka
Tel: +421 2 5810 1Italia
Boehringer Ingelheim Italia S.p.A.
Tel: +39 02 5355 1
Suomi/Finland
Boehringer Ingelheim Finland Ky
Puh/Tel: +358 10 3102<br />
Boehringer Ingelheim Ellas A.E.
T : +30 2 10 89 06 Sverige
Boehringer Ingelheim AB 
Tel: +46 8 721 21 Latvija
Boehringer Ingelheim RCV GmbH &amp; Co KG
Latvijas fili le
Tel: +371 67 240 United Kingdom (Northern Ireland)
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-2a9a5e18ea12db555fa903817024b9fe
InstanceOf: CompositionUvEpi
Title: "Composition for mirapexin Package Leaflet"
Description:  "Composition for mirapexin Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpab95c79ec7ceeaa38bc48db0210fa26a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - mirapexin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen:
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Mirapexin
3. Sådan skal du tage Mirapexin
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What mirapexin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What mirapexin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mirapexin indeholder det aktive stof pramipexol, og tilhører en gruppe lægemidler, der kaldes 
dopaminagonister, som stimulerer (dopaminreceptorerne i hjernen. Stimulering af 
dopaminreceptorerne udløser nerveimpulser i hjernen, som hjælper med at kontrollere kroppens 
bevægelser.
Mirapexin bruges til behandling af voksne patienter med symptomer på Parkinsons sygdom. 
Mirapexin kan tages alene eller i kombination med levodopa (anden medicin til behandling af 
Parkinsons sygdom)</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take mirapexin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take mirapexin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke Mirapexin</h2>
<p>hvis du er allergisk over for pramipexol eller et af de øvrige indholdsstoffer i Mirapexin
(angivet i punkt 6).
Advarsler og forsigtighedsregler
Kontakt lægen, før du tager Mirapexin. Fortæl det til din læge, hvis du har eller har haft eller udvikler 
nogle sygdomme eller symptomer, især nogle af følgende:

Nyresygdomme

Hallucinationer (ser, hører eller føler ting, som ikke er der). De fleste hallucinationer er syns-
hallucinationer

Dyskinesi (f.eks. unormale, ufrivillige bevægelser af arme og ben)
80
Hvis du har Parkinsons sygdom i fremskreden grad og samtidig behandles med levodopa, kan der 
være risiko for udvikling af dyskinesi, når Mirapexin-dosis øges

Dystoni (manglende evne til at holde din krop og nakke lige og oprejst (aksial dystoni)). Du kan 
især opleve, at dit hoved og din nakke falder forover (denne tilstand kaldes antecollis), at din 
lænd bøjer forover (denne tilstand kaldes camptocormia), eller at din ryg falder til siden (denne 
tilstand kaldes pleurothotonus eller Pisa-syndrom)

Søvnighed og episoder med pludseligt indsættende søvn

Psykoser (f.eks. som ved symptomer på skizofreni)

Synsnedsættelse. Så længe du er i behandling med Mirapexin, anbefales det at få øjnene 
undersøgt regelmæssigt

Alvorlige hjerte- eller karsygdomme. Dit blodtryk skal kontrolleres regelmæssigt, især i starten 
af behandlingen. Dette er for at undgå postural hypotension (et blodtryksfald, når du for 
eksempel rejser dig op).
Fortæl din læge, hvis du eller din familie/pårørende bemærker, at du er ved at udvikle trang til at 
opføre dig på måder, der er usædvanlige for dig, og du ikke kan modstå trangen eller fristelsen til at 
udføre visse aktiviteter, der kan skade dig selv eller andre. Dette kaldes manglende impulskontrol og 
kan omfatte adfærd som ludomani, overdreven madindtagelse eller trang til indkøb, en unormal stor 
sexlyst eller sex-interesse med en stigning i seksuelle tanker eller følelser. Din læge skal muligvis 
justere din dosis eller afbryde behandlingen.
Fortæl din læge, hvis du eller din familie/pårørende bemærker, at du er ved at udvikle mani (føle sig 
oprørt, opstemt eller ophidset) eller delirium (nedsat bevidsthed, forvirring eller manglende 
realitetsopfattelse). Din læge skal muligvis justere din dosis eller afbryde behandlingen.
Fortæl din læge, hvis du oplever symptomer såsom depression, apati, angst, træthed, svedtendens eller 
smerter, efter at du er stoppet med eller har nedsat dosis i din Mirapexin-behandling. Hvis problemet 
varer længere end et par uger, skal din læge muligvis justere din behandling.
Fortæl det til din læge, hvis du udvikler en manglende evne til at holde din krop og nakke lige og 
oprejst (aksial dystoni). Hvis dette sker, kan det være, at lægen vil justere eller ændre din medicin.
Mirapexin-depottabletter er specialfremstillede tabletter, hvor det aktive stof langsomt frigives efter 
indtagelse af tabletten. Dele af tabletterne kan lejlighedsvis passere gennem systemet og udskilles i 
afføringen, hvor de kan ligne hele tabletter. Fortæl det til lægen, hvis du finder tabletstykker i din 
afføring.
Børn og unge
Børn og unge under 18 år bør ikke bruge Mirapexin.
Brug af andre lægemidler sammen med Mirapexin
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget
andre lægemidler eller planlægger at tage andre lægemidler. Dette gælder også medicin, 
naturlægemidler, helsekost eller tilskud, som du har fået uden recept.
Du bør undgå at tage medicin mod psykiske lidelser (antipsykotika) sammen med Mirapexin.
Vær forsigtig, hvis du tager følgende medicin:

cimetidin (til at behandle for meget mavesyre og mavesår)

amantadin (kan anvendes til at behandle Parkinsons sygdom)

mexitil (til at behandle uregelmæssig hjerterytme, en tilstand, der kaldes ventrikelarytmi)

zidovudin (kan anvendes til at behandleerhvervet immundefekt syndrom (aids), en sygdom i 
immunsystemet hos mennesker

cisplatin (til at behandle forskellige typer kræft)

quinin (kan anvendes til forebyggelse af smertefulde natlige kramper i benene og til behandling 
af en malariatype kendt som falciparum malaria (ondartet malaria))
81

procainamid (til at behandle uregelmæssig hjerterytme)
Hvis du tager levodopa, anbefales det at nedsætte dosis, når du starter behandling med Mirapexin.
Vær forsigtig, hvis du tager beroligende medicin eller drikker alkohol, da Mirapexin kan påvirke din 
evne til at føre motorkøretøj og betjene maskiner.
Brug af Mirapexin sammen med mad, drikke og alkohol
Ved behandling med Mirapexin, skal du være forsigtig med indtagelse af alkohol.
Mirapexin kan enten tages sammen med mad eller alene.
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. Din læge vil tale med dig, om du skal 
fortsætte med at tage Mirapexin.
Det er ukendt, hvilken virkning Mirapexin kan have på det ufødte barn. Derfor må du ikke tage 
Mirapexin, hvis du er gravid, medmindre din læge anbefaler dig at gøre det.
Mirapexin må ikke anvendes under amning. Mirapexin kan nedsætte mælkeproduktionen og kan også 
overføres til din baby via brystmælk. Hvis du ikke kan undvære Mirapexin, bør amningen stoppe.
Spørg din læge eller apotekspersonalet til råds, før du tager nogen form for medicin.
Trafik- og arbejdssikkerhed
Mirapexin kan give hallucinationer (du ser, hører eller føler ting, der ikke er der). Hvis du påvirkes af 
dette, må du ikke føre motorkøretøj eller betjene maskiner.
Mirapexin er blevet forbundet med søvnighed og pludselig indsættende søvn, specielt for 
Parkinsonpatienter. Du må ikke føre motorkøretøj eller betjene maskiner, hvis du oplever disse 
bivirkninger. Du bør fortælle det til din læge, hvis dette sker.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take mirapexin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take mirapexin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. Lægen vil rådgive 
dig om den rette dosering.
Mirapexin-depottabletter skal tages en gang daglig, og hver dag på ca. det samme tidspunkt.
Mirapexin-tabletter bør synkes hele med vand, og kan både tages sammen med eller uden mad.
Du må ikke tygge, dele eller knuse 
depottabletterne. Hvis du gør det, er der risiko 
for overdosering, da medicinen derved kan blive 
frigivet for hurtigt i kroppen.
I den første uge er den sædvanlige daglige dosis 0,26 mg pramipexol. Lægen vil normalt anvise, at den 
daglige dosis øges hver 5.-7. dag indtil dine symptomer er under kontrol (vedligeholdelsesdosis).
Skema for stigende doser af Mirapexin-depottabletter
Uge
Daglig dosis (mg)
Antal tabletter
1
0,26
1 Mirapexin 0,26 mg depottablet.
82
2
0,52
1 Mirapexin 0,52 mg depottablet,
ELLER
2 Mirapexin 0,26 mg depottabletter.
3
1,05
1 Mirapexin 1,05 mg depottablet,
ELLER
2 Mirapexin 0,52 mg depottabletter,
ELLER
4 Mirapexin 0,26 mg depottabletter.
Den sædvanlige vedligeholdelsesdosis er 1,05 mg daglig. Det kan imidlertid være nødvendigt at øge 
din dosis yderligere. I så fald kan lægen øge din dosis op til maksimalt 3,15 mg pramipexol/dag. En
lavere vedligeholdelsesdosis på 1 Mirapexin 0,26 mg depottablet/dag er også mulig.
Patienter med nyresygdomme
Hvis du har en nyresygdom, vil din læge eventuelt anbefale dig kun at tage den sædvanlige startsdosis 
på 0,26 mg depottablet hveranden dag den første uge. Derefter vil din læge muligvis øge dosis til én 
0,26 mg depottablet hver dag. Hvis yderligere dosisøgning er nødvendig, vil din læge øge dosis
trinvist med 0,26 mg pramipexol.
Hvis du har en alvorlig nyresygdom, kan lægen have behov for at skifte dig til en anden type 
pramipexolmedicin. Kontakt din læge med det samme, hvis du oplever en forværring i din 
nyresygdom under behandlingen.
Hvis du skifter fra Mirapexin-tabletter med hurtig udløsning (dine almindelig tabletter)
Din læge vil basere din dosis af Mirapexin-depottabletter på den dosis af Mirapexin-tabletter med 
hurtig udløsning, som du hidtil har taget.
Tag dine Mirapexin-tabletter med hurtig udløsning som normalt dagen før, du skifter. Tag Mirapexin-
depottabletter den næste morgen, og tag så ikke flere Mirapexin-tabletter med hurtig udløsning.
Hvis du har taget for meget Mirapexin
Hvis du utilsigtet har taget for mange tabletter, skal du
-
kontakte lægen eller skadestuen med det samme for rådgivning.
-
Du kan opleve opkastning, rastløshed eller nogle af bivirkningerne, der er anført under punkt 4 
"Bivirkninger".
Hvis du har glemt at tage Mirapexin
Hvis du har glemt at tage en Mirapexin dosis, men kommer i tanke om det inden for 12 timer fra det 
sædvanlige tidspunkt, hvor du skulle have taget en dosis, skal du straks tage din tablet. Herefter
fortsætter du med at tage den næste tablet på sædvanligt tidspunkt.
Hvis der er gået mere end 12 timer, skal du blot tage næste enkeltdosis på det sædvanlige tidspunkt. 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
Hvis du holder op med at tage Mirapexin
Du må ikke holde op med at tage Mirapexin uden først at tale med din læge. Hvis det er nødvendigt at 
holde op med at tage dette lægemiddel, vil lægen nedsætte din dosis gradvist. Dette mindsker risikoen 
for, at symptomerne forværres.
Hvis du har Parkinsons sygdom, bør du ikke stoppe behandlingen med Mirapexin pludseligt, da det 
kan medføre en sygelig tilstand kaldet malignt neuroleptikasyndrom, der kan udgøre en alvorlig 
helbredsrisiko. Symptomerne er blandt andet:

akinesi (nedsat evne til at bevæge musklerne)

muskelstivhed

feber

ustabilt blodtryk

takykardi (øget hjerterytme)

forvirring
83

påvirket bevidsthedstilstand, (f.eks. koma)
Hvis du holder op med eller nedtrapper Mirapexin, kan du også udvikle en sygelig tilstand kaldet 
dopaminagonist-abstinenssyndrom. Symptomerne omfatter depression, apati, angst, træthed, 
svedtendens eller smerter. Hvis du får disse symptomer, skal du kontakte din læge.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Evalueringen af disse bivirkninger er baseret på de følgende hyppigheder:
Meget almindelig
Kan forekomme hos flere end 1 ud af 10 personer
Almindelig
Kan forekomme hos op til 1 ud af 10 personer
Ikke almindelig
Kan forekomme hos op til 1 ud af 100 personer
Sjælden
Kan forekomme hos op til 1 ud af 1.000 personer
Meget sjælden
Kan forekomme hos op til 1 ud af 10.000 personer
Ikke kendt
Hyppigheden kan ikke estimeres ud fra forhåndenværende data
Du kan få følgende bivirkninger:
Meget almindelig:

Dyskinesi (f.eks. unormale, ufrivillige bevægelser af arme og ben)

Søvnighed

Svimmelhed

Kvalme
Almindelig:

Trang til unormal adfærd

Hallucinationer (du ser, hører eller føler ting, som ikke er der)

Forvirring

Træthed (udmattelse)

Søvnløshed (insomni)

Væskeophobning, normalt i benene (perifert ødem)

Hovedpine

Hypotension (lavt blodtryk)

Unormale drømme

Forstoppelse

Synsnedsættelse

Opkastning

Vægttab, herunder nedsat appetit
Ikke almindelig:

Paranoia (såsom overdreven frygt for sit helbred)

Vrangforestillinger

Udtalt træthed om dagen og episoder med pludselig indsættende søvn

Amnesi (hukommelsestab)

Hyperkinesi (øget muskelaktivitet med ufrivillige bevægelser)

Vægtforøgelse

Allergiske reaktioner (f.eks. udslæt, kløe, overfølsomhed)

Besvimelse

Hjertesvigt (hjerteproblemer, der kan forårsage åndenød eller hævede ankler)<em> 
Uhensigtsmæssig udskillelse af antidiuretisk hormon</em> 84

Rastløshed

Dyspnø (åndenød)

Hikke

Pneumoni (lungebetændelse)

Manglende evne til at modstå trangen eller fristelsen til at udføre en handling, der kan være 
skadelig for dig selv eller andre, og som kan omfatte:
-
Stærk trang til at spille (sygelig spilletrang) trods alvorlige personlige og familiemæssige 
konsekvenser.
-
Ændret eller øget seksuel interesse og adfærd, der vækker stor bekymring hos dig eller 
andre, for eksempel en øget seksualdrift.
-
Ukontrollerbart overdrevent indkøbsmønster og forbrug.
-
Uhæmmet madindtagelse (spise store mængder mad i en kort periode) eller overdreven 
madindtagelse (spise mere mad end sædvanligt og mere end nødvendigt for at dække 
sulten)<em> 
Delirium (nedsat bevidsthed, forvirring, manglende realitetsopfattelse)
Sjælden:

Mani (føle sig oprørt, opstemt eller ophidset)

Spontan erektion af penis
Ikke kendt:
-
Efter at du er stoppet med eller har nedsat din Mirapexin-behandling: Depression, apati, angst, 
træthed, svedtendens eller smerter kan forekomme (kaldet dopaminagonist-abstinenssyndrom 
eller dopamine agonist withdrawal syndrome - DAWS).
Fortæl din læge, hvis du oplever nogle af disse adfærdsmønstre; han vil diskutere måder til at 
håndtere eller mindske symptomerne.
For de bivirkninger, der er markeret med </em>, er en præcis vurdering af hyppigheden ikke mulig, da 
disse bivirkninger ikke blev set i kliniske studier med 2.762 patienter behandlet med pramipexol. 
Hyppighedskategorien er formentlig ikke større end "ikke almindelig".
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store mirapexin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store mirapexin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned.
Opbevares i den originale yderpakning for at beskytte mod fugt.
Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel.
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.
85</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mirapexin indeholder:
Aktivt stof: pramipexol.
Hver tablet indeholder 0,26 mg, 0,52 mg, 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg eller 3,15 mg 
pramipexol som henholdsvis 0,375 mg, 0,75 mg, 1,5 mg, 2,25 mg, 3 mg, 3,75 mg eller 4,5 mg 
pramipexoldihydrochloridmonohydrat.
Øvrige indholdsstoffer: hypromellose 2208, majsstivelse, carbomer 941, kolloid vandfri silica, 
magnesiumstearat.
Udseende og pakningsstørrelser
Mirapexin 0,26 mg og 0,52 mg depottabletter er hvide til råhvide, runde og har facetslebne kanter.
Mirapexin 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg og 3,15 mg depottabletter er hvide til råhvide og ovale.
Alle tabletter har Boehringer Ingelheim firmasymbol præget på den ene side og koden P1, P2, P3, 
P12, P4, P13 eller P5 på den anden side gældende for tablet styrkerne 0,26 mg, 0,52 mg, 1,05 mg, 
1,57 mg, 2,1 mg, 2,62 mg og 3,15 mg.
Alle styrker af Mirapexin findes i -blisterstrips af aluminium med 10 tabletter pr. strip. Hver æske
indeholder 1, 3 eller 10 blisterstrips (10, 30 eller 100 depottabletter). Ikke alle pakningsstørrelser er 
nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Tyskland
Fremstiller
Boehringer Ingelheim Pharma GmbH &amp; Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Rottendorf Pharma GmbH
Ostenfelder Strasse 51 - 61
59320 Ennigerloh
Tyskland
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
Frankrig
86
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Lietuva
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Lietuvos filialas
Tel: +370 5 2595942
България
Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ -
клон България
Тел: +359 2 958 79 98
Luxembourg/Luxemburg
Boehringer Ingelheim SComm
Tél/Tel: +32 2 773 33 11
Česká republika
Boehringer Ingelheim spol. s r.o.
Tel: +420 234 655 111
Magyarország
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Magyarországi Fióktelepe
Tel: +36 1 299 89 00
Danmark
Boehringer Ingelheim Danmark A/S
Tlf: +45 39 15 88 88
Malta
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Deutschland
BIOTHERAX biochemisch-pharmazeutische 
Gesellschaft mbH
Tel: +49 (0) 800 77 90 900
Nederland
Boehringer Ingelheim B.V.
Tel: +31 (0) 800 22 55 889
Eesti
Boehringer Ingelheim RCV GmbH &amp; Co KG
Eesti filiaal
Tel: +372 612 8000
Norge
Boehringer Ingelheim Danmark Norwegian branch
Tlf: +47 66 76 13 00
Ελλάδα
Boehringer Ingelheim Ελλάς Μονοπρόσωπη A.E.
Tηλ: +30 2 10 89 06 300
Österreich
Boehringer Ingelheim RCV GmbH &amp; Co KG
Tel: +43 1 80 105-7870
España
Boehringer Ingelheim España, S.A.
Tel: +34 93 404 51 00
Polska
Boehringer Ingelheim Sp.zo.o.
Tel: +48 22 699 0 699
France
Boehringer Ingelheim France S.A.S.
Tél: +33 3 26 50 45 33
Portugal
Boehringer Ingelheim Portugal, Lda.
Tel: +351 21 313 53 00
Hrvatska
Boehringer Ingelheim Zagreb d.o.o.
Tel: +385 1 2444 600
România
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena -
Sucursala Bucureşti
Tel: +40 21 302 2800
Ireland
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Slovenija
Boehringer Ingelheim RCV GmbH &amp; Co KG 
Podružnica Ljubljana
Tel: +386 1 586 40 00
87
Ísland
Vistor hf.
Sími: +354 535 7000
Slovenská republika
Boehringer Ingelheim RCV GmbH &amp; Co KG
organizačná zložka
Tel: +421 2 5810 1211
Italia
Boehringer Ingelheim Italia S.p.A.
Tel: +39 02 5355 1
Suomi/Finland
Boehringer Ingelheim Finland Ky
Puh/Tel: +358 10 3102 800
Κύπρος
Boehringer Ingelheim Ελλάς Μονοπρόσωπη A.E.
Tηλ: +30 2 10 89 06 300
Sverige
Boehringer Ingelheim AB
Tel: +46 8 721 21 00
Latvija
Boehringer Ingelheim RCV GmbH &amp; Co KG
Latvijas filiāle
Tel: +371 67 240 011
United Kingdom (Northern Ireland)
Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-2a9a5e18ea12db555fa903817024b9fe
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for mirapexin Package Leaflet for language en"
Description: "ePI document Bundle for mirapexin Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-2a9a5e18ea12db555fa903817024b9fe"
* entry[0].resource = composition-en-2a9a5e18ea12db555fa903817024b9fe

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2a9a5e18ea12db555fa903817024b9fe"
* entry[=].resource = mp2a9a5e18ea12db555fa903817024b9fe
                            
                    
Instance: bundlepackageleaflet-da-2a9a5e18ea12db555fa903817024b9fe
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for mirapexin Package Leaflet for language da"
Description: "ePI document Bundle for mirapexin Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-2a9a5e18ea12db555fa903817024b9fe"
* entry[0].resource = composition-da-2a9a5e18ea12db555fa903817024b9fe

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2a9a5e18ea12db555fa903817024b9fe"
* entry[=].resource = mp2a9a5e18ea12db555fa903817024b9fe
                            
                    



Instance: mp2a9a5e18ea12db555fa903817024b9fe
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product mirapexin"
Description: "mirapexin"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "MIRAPEXIN 0.088 mg tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "MIRAPEXIN is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "mirapexin"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 2a9a5e18ea12db555fa903817024b9feListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "mirapexin"

* status = #current
* mode = #working

* title = "List of all ePIs associated with mirapexin"

* subject = Reference(mpab95c79ec7ceeaa38bc48db0210fa26a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#mirapexin "mirapexin"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-2a9a5e18ea12db555fa903817024b9fe) // mirapexin en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-2a9a5e18ea12db555fa903817024b9fe) // mirapexin da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-2a9a5e18ea12db555fa903817024b9fe
InstanceOf: List

* insert 2a9a5e18ea12db555fa903817024b9feListRuleset
    